Stockreport

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD. Top-line data from the study sho [Read more]